Charalambos (Babis) Andreadis, MD, MSCE – University of California San FranciscoNina Shah, MD – University of California San FranciscoSamantha Shenoy, NP – UCSF Medical CenterRegistration:Registration for this program is now closed.
Multiple Myeloma: BiTE therapy and New Immunotherapy on The HorizonNina Shah, MD – University of California San Francisco
Multiple Myeloma and CAR T therapySurbhi Sidana, MD – Stanford University
ALL and CAR T therapyAaron Logan, MD, PhD – University of California San Francisco
PD1, CD47 and other immune based approaches in AMLNaval Daver, MD – The University of Texas MD Anderson Cancer Center
Check point Inhibitors in HL and NHLMichael Spinner, MD – Stanford University
NHL and ImmunotherapyCharalambos (Babis) Andreadis, MD, MSCE – University of California San Francisco
Practical Aspects of Immunotherapy ManagementSamantha Shenoy, NP – UCSF Medical Center
Faculty PanelCharalambos (Babis) Andreadis, MD, MSCE – University of California San FranciscoNaval Daver, MD – The University of Texas MD Anderson Cancer CenterAaron Logan, MD, PhD – University of California San FranciscoNina Shah, MD – University of California San FranciscoSamantha Shenoy, NP – UCSF Medical CenterSurbhi Sidana, MD – Stanford UniversityMichael Spinner, MD – Stanford University
Program Learning Objectives
Case Study Submission Information:Case study submissions are now closed.Target AudienceThe Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute of Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Postgraduate Institute of Medicine designates this continuing education activity for 1.75 Pharmacotherapy contact hours for Advance Practice Registered Nurses.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.
Americans with Disabilities ActEvent staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email firstname.lastname@example.org.
The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 1/19/2022)
The 2021-2022 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Association of Community Cancer Centers, Advances Practitioner Society for Hematology and Oncology, and Hematology/Oncology Pharmacy Association. This program is provided in collaboration with the American Academy of Emergency Medicine.
Technology Information and Policy
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com